Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14065
Abstract: Background: BEVZ92 has being developed as a proposed biosimilar approved reference medicine product (RMP). BEVZ92 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to RMP. The aim of… read more here.
Keywords: compared rmp; treatment; results bevacizumab; biosimilar compared ... See more keywords